Biotech Values

[pcrutch]

Other AASLD abstracts I missed for $VRTX's Incivek that could be of interest

"#LB-8. Telaprevir Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Coinfected Patients: 24-Week Treatment Interim Analysis."

"#LB-23. Validation of an HCV NS3/4A Sequencing Assay for Evaluating Resistance to Boceprevir, Telaprevir and Protease Inhibitor Candidates in a Clinical Reference Laboratory Setting."

"#248. Follow-up of SVR Durability and Viral Resistance in Patients with Chronic Hepatitis C Treated with Telaprevir-Based Regimens: Interim Analysis of the EXTEND Study."

"#31. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study."

"#32. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the Phase III REALIZE study."

"#35. Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219)"

"#2117. Importance of newly described rare hepatitis C virus NS3 protease resistance mutations in patients treated with telaprevir or boceprevir."

"#2104. Long-term follow-up analysis of the hepatitis C virus NS3 protease in patients treated with telaprevir or boceprevir – a comparison between clonal and deep sequencing."

"#2088. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain From Wild Type Clone in Vivo."

#2105. Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated with a Telaprevir-Based Regimen Regardless of Liver Fibrosis Stage."